Somatostatin

Somatostatin is a cyclic peptide hormone produced primarily in the hypothalamus (14-amino acid form, somatostatin-14) and the gastrointestinal tract (28-amino acid form, somatostatin-28). Despite its relatively simple structure, somatostatin exerts astonishingly broad inhibitory effects throughout the body through five subtypes of G-protein-coupled receptors (SSTR1-SSTR5) that are widely distributed across the pituitary, pancreas, gut, brain, and many other tissues.

The discovery of somatostatin in 1973 by Brazeau and colleagues in Guillemin's laboratory (while searching for GHRH) was initially surprising: rather than a stimulating factor for GH, they found a potent inhibitory factor. The name "somatostatin" - from the Greek for "body standstill" - reflects this inhibitory character. Guillemin shared the 1977 Nobel Prize in Physiology or Medicine partly for this discovery.

In the context of GH regulation, somatostatin is the physiological counterbalance to GHRH. Somatostatin neurons in the periventricular nucleus of the hypothalamus tonically inhibit GH secretion, and the pulsatile nature of GH release in normal physiology reflects alternating episodes of GHRH dominance (producing GH pulses) and somatostatin dominance (suppressing secretion between pulses). The clinical relevance of this opposing system is evident in acromegaly - GH-secreting pituitary adenomas are often partially responsive to somatostatin analogues because they retain SSTR2 and SSTR5 expression, making pharmacological somatostatin one of the primary treatments for this condition.

The pancreatic actions of somatostatin represent another clinically important dimension. D-cells in the pancreatic islets produce somatostatin in response to meals, acting in a paracrine manner to dampen both insulin (from beta cells) and glucagon (from alpha cells) secretion. This provides a feedback brake on post-meal hormonal responses, preventing excessive insulin and glucagon surges. In the context of type 2 diabetes, somatostatin's role in modulating glucagon secretion (which is inappropriately elevated in T2D) has attracted therapeutic interest.

The oncological applications of somatostatin pharmacology represent one of the most important developments in modern oncology. Neuroendocrine tumours (NETs) - a heterogeneous group of cancers arising from neuroendocrine cells throughout the body - frequently overexpress somatostatin receptors (particularly SSTR2), making them visible on somatostatin receptor scintigraphy and amenable to treatment with somatostatin analogues. Octreotide and lanreotide have been shown in randomised trials to significantly prolong progression-free survival in midgut NETs - one of the first "targeted" therapies in oncology. The development of PRRT (peptide receptor radionuclide therapy), where a radiolabelled somatostatin analogue (lutetium-177-DOTATATE/Lutathera) delivers targeted radiation to SSTR-expressing tumour cells, has further transformed the treatment of advanced NETs.

The gastrointestinal effects of somatostatin reflect its role as a broad inhibitory signal in the gut. Somatostatin suppresses gastric acid secretion, pancreatic enzyme secretion, bile flow, intestinal motility, and splanchnic blood flow. These properties are exploited clinically in the acute management of upper GI bleeding (where IV somatostatin or octreotide reduces portal pressure and variceal bleeding) and in the control of high-output enterocutaneous fistulas and secretory diarrhoea. The side effect profile of long-term somatostatin analogue use - gallstones, steatorrhoea, impaired GI motility - directly reflects these inhibitory GI actions.